EP3890740
CD70 og venetóklax, BCL-2 hindri, samsett meðferð til meðhöndlunar á bráðu mergfrumuhvítblæði
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
18.12.2019EP published:
1.3.2023EP application number:
19831677.0
EP translation filed:
3.4.2023Grant published:
15.5.2023EPO information:
European Patent Register
Max expiry date:
17.12.2039Expiry date:
17.12.2026Next due date:
31.12.2026
Title in English:
CD70 AND VENETOCLAX, A BCL-2 INHIBITOR, COMBINATION THERAPY FOR TREATING ACUTE MYELOID LEUKEMIALanguage of the patent:
English
Timeline
Today
18.12.2019EP application
1.3.2023EP Publication
3.4.2023Translation submitted
15.5.2023Registration published
17.12.2026Expires
Owner
Name:
Argenx BVBAAddress:
Industriepark Zwijnaarde 7, 9052 Gent, BE
Name:
University of BernAddress:
Verwaltungsdirektion Hochschulstrasse 6, 3012 Bern, CH
Inventor
Name:
DE HAARD, HansAddress:
9052 Gent, BE
Name:
FUNG, SamsonAddress:
9052 Gent, BE
Name:
LEUPIN, NicolasAddress:
9052 Gent, BE
Name:
VAN ROMPAEY, LucAddress:
9052 Gent, BE
Name:
OCHSENBEIN, AdrianAddress:
3012 Bern, CH
Name:
RIETHER, CarstenAddress:
3012 Bern, CH
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201820582Date:
18.12.2018Country:
GB
Number:
201911007Date:
1.8.2019Country:
GB
Number:
201917701Date:
4.12.2019Country:
GB
Classification
Categories:
A61K 31/496, A61K 39/395, A61P 35/00, C07D 471/04, C07K 16/28
Annual fees
Number
Paid
Expires
Payer
Number: 5
Paid: 15.11.2023
Expires: 17.12.2024
Payer: Árnason Faktor ehf.
Number: 6
Paid: 10.12.2024
Expires: 17.12.2025
Payer: Árnason Faktor ehf.
Number: 7
Paid: 15.12.2025
Expires: 17.12.2026
Payer: Árnason Faktor ehf.